Evidence map›Paper›PMID 35624764›Full record

ArticleAntioxidants (Basel, Switzerland)2022

Paraoxonase-1 Regulation of Renal Inflammation and Fibrosis in Chronic Kidney Disease.

Fatimah K Khalaf, Chrysan J Mohammed, Prabhatchandra Dube, Jacob A Connolly, Apurva Lad, Usman M Ashraf, Joshua D Breidenbach, Robin C Su, Andrew L Kleinhenz, Deepak Malhotra and 3 more

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Observational
  2. Review
  3. The Paraoxonase (International journal of molecular sciences · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Paraoxonases at the Heart of Neurological Disorders.International journal of molecular sciences · 2023
    Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Fatimah K KhalafDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.ORCID 0000-0002-1997-0977
Chrysan J MohammedDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.
Prabhatchandra DubeDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.
Jacob A ConnollyDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.
Apurva LadDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.
Usman M AshrafDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.
Joshua D BreidenbachDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.ORCID 0000-0002-5892-1879
Robin C SuDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.
Andrew L KleinhenzDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.
Deepak MalhotraDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.
Amira F GoharaDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.ORCID 0000-0001-7068-2244
Steven T HallerDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.ORCID 0000-0002-6919-6342
David J KennedyDepartment of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA.ORCID 0000-0001-5265-0142
University of Toledo · USUniversity of Alkafeel · IQ

Funding

Counter regulatory mechanisms of cardiotonic steroids in cardio-renal syndromeR01HL137004 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI KENNEDY, DAVID JOSEPH · 2017 to 2021
$1.9M
Inhalation Exposure to Aerosolized Cyanotoxins Worsens Pre-Existing Asthma via Activation of Granulocytic InflammationF31HL160178 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI BREIDENBACH, JOSHUA DAVID · 2021 to 2022
$60k
NHLBI NIH HHS F31 HL160178NHLBI NIH HHS R01 HL137004
6 · The paper itself

Abstract

Papraoxonase-1 (PON1) is a hydrolytic lactonase enzyme that is synthesized in the liver and circulates attached to high-density lipoproteins (HDL). Clinical studies have demonstrated an association between diminished PON-1 and the progression of chronic kidney disease (CKD). However, whether decreased PON-1 is mechanistically linked to renal injury is unknown. We tested the hypothesis that the absence of PON-1 is mechanistically linked to the progression of renal inflammation and injury in CKD. Experiments were performed on control Dahl salt-sensitive rats (SSMcwi, hereafter designated SS rats) and Pon1 knock-out rats (designated SS-Pon1em1Mcwi, hereafter designated SS-PON-1 KO rats) generated by injecting a CRISPR targeting the sequence into SSMcwi rat embryos. The resulting mutation is a 7 bp frameshift insertion in exon 4 of the PON-1 gene. First, to examine the renal protective role of PON-1 in settings of CKD, ten-week-old, age-matched male rats were maintained on a high-salt diet (8% NaCl) for up to 5 weeks to initiate the salt-sensitive hypertensive renal disease characteristic of this model. We found that SS-PON-1 KO rats demonstrated several hallmarks of increased renal injury vs. SS rats including increased renal fibrosis, sclerosis, and tubular injury. SS-PON-1 KO also demonstrated increased recruitment of immune cells in the renal interstitium, as well as increased expression of inflammatory genes compared to SS rats (all p < 0.05). SS-PON-1 KO rats also showed a significant (p < 0.05) decline in renal function and increased renal oxidative stress compared to SS rats, despite no differences in blood pressure between the two groups. These findings suggest a new role for PON-1 in regulating renal inflammation and fibrosis in the setting of chronic renal disease independent of blood pressure.

Indexed as

chronic kidney diseasefibrosisinflammationparaoxonase-1

Identifiers

PMID35624764
PMCPMC9137734
OpenAlexW4225247837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.